3
Announcements
Trials
Browse
Landscape
Status
Completed
1
Sponsor Class
OTHER
1
Study Type
Observational
1
Sponsor
Cancer Type
Sarcoma
1
Dermatologic
1
Conditions
Carcinoma, Basal Cell
6
Skin Neoplasms
4
Carcinoma, Squamous Cell
3
Recurrence
2
Dermatofibrosarcoma
2
Surgical Wound
1
Postoperative Complications
1
Neoplasms, Adnexal and Skin Appendage
1
Melanoma
1
Hutchinson's Melanotic Freckle
1
Histiocytoma, Malignant Fibrous
1
Eyelid Neoplasms
1
Cicatrix
1
Adenocarcinoma, Sebaceous
1
Interventions
Radiotherapy
6
Doxorubicin
5
Nivolumab
4
pembrolizumab
3
Sunitinib
3
Ifosfamide
3
Gemcitabine
3
Docetaxel
3
pazopanib
2
Radiation Dose Hypofractionation
2
Radiation
2
Methotrexate
2
Ipilimumab
2
Cisplatin
2
CTLA-4 Antigen
2
3-(5-fluorobenzofuran-3-yl)-4-(5-methyl-5H-(1,3)dioxolo(4,5-f)indol-7-yl)-pyrrole-2,5-dione
2
tremelimumab
1
toripalimab
1
temsirolimus
1
spartalizumab
1
sintilimab
1
ribociclib
1
regorafenib
1
pegfilgrastim
1
liposomal doxorubicin
1
lentiviral minigene vaccine of COVID-19 coronavirus
1
itacitinib
1
fludarabine
1
eribulin
1
durvalumab
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
OTHER
×
Histiocytoma, Malignant Fibrous
×
Mohs Surgery
×
Clear all
NCT02310503
2020-05-05
REGESMOHS
Fundación Academia Española de Dermatología
Completed
6,000 enrolled